Stifel Nicolaus analyst Annabel Samimy reiterated a Buy rating on RegenXBio (RGNX – Research Report) today and set a price target of $40.00. The company’s shares closed yesterday at $10.15. Don't Miss ...
GET MORE AI-GENERATED SIGNALS: November 14, 2024, 18:38 pm ET, BY Tyler- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has received an average recommendation of “Moderate Buy” from the twelve brokerages that are covering the firm, MarketBeat reports. One research analyst ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Regenxbio Inc (RGNX) reports strong progress in late-stage programs and maintains a robust cash position to fund operations ...
REGENXBIO stock is trading higher on Monday after the company reached a critical point in its trial for Duchenne gene therapy.
Across the recent three months, 5 analysts have shared their insights on Regenxbio RGNX, expressing a variety of opinions ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback